欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Lanopepden Mesylate_1441390-17-5_产品详情
1441390-17-5
  • Lanopepden Mesylate

  • names:

    N-((R)-2-(Cyclopentylmethyl)-3-(2-(5-fluoro-6-((S)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-2-methylpyrimidin-4-yl)hydrazineyl)-3-oxopropyl)-N-hydroxyformamide Mesylate

  • CAS号:

    1441390-17-5

    MDL Number:
  • MF(分子式): C23H38FN7O7S MW(分子量): 575.6574
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Lanopepden Mesylate
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名 Lanopepden Mesylate
英文别名 GSK-1322322A; GSK 1322322A; GSK1322322A; GSK-322A; GSK 322A; GSK322A
CAS号 1441390-17-5
Inchi InChI=1S/C22H34FN7O4.CH4O3S/c1-15-24-20(19(23)21(25-15)29-7-6-28-8-9-34-13-18(28)12-29)26-27-22(32)17(11-30(33)14-31)10-16-4-2-3-5-16;1-5(2,3)4/h14,16-18,33H,2-13H2,1H3,(H,27,32)(H,24,25,26);1H3,(H,2,3,4)/t17-,18+;/m1./s1
InchiKey UNGNACZMQRGYNV-URBRKQAFSA-N
分子式 Formula C23H38FN7O7S
分子量 Molecular Weight 575.6574
溶解度Solubility
性状 Solid powder
储藏条件 Storage conditions Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).
产品说明 Lanopepden Mesylate(CAS:1441390-17-5):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。
IntroductionLanopepden Mesylate is a novel peptide deformylase inhibitor against streptococcus pneumoniae, haemophilus influenzae, and staphylococcus aureus
Application1
Application2
Application3
警示图
危险性 Warning
危险性警示
安全声明
安全防护
备注
[1]Maral S, Bakanay SM, Kucuksahin O, Dilek I. Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib. J Oncol Pharm Pract. 2019 Jul 30:1078155219863469. doi: 10.1177/1078155219863469. [Epub ahead of print] PubMed PMID: 31359838.
[2]Li G, Chan YL, Sukjamnong S, Anwer AG, Vindin H, Padula M, Zakarya R, George J, Oliver BG, Saad S, Chen H. A Mitochondrial Specific Antioxidant Reverses Metabolic Dysfunction and Fatty Liver Induced by Maternal Cigarette Smoke in Mice. Nutrients. 2019 Jul 21;11(7). pii: E1669. doi: 10.3390/nu11071669. PubMed PMID: 31330878.
[3] Lind J, Czernilofsky F, Vallet S, Podar K. Emerging protein kinase inhibitors for the treatment of multiple myeloma. Expert Opin Emerg Drugs. 2019 Jul 29:1-20. doi: 10.1080/14728214.2019.1647165. [Epub ahead of print] PubMed PMID: 31327278.
[4] Hung KD, Van QL, Hoang GN, Bich PNT. Imatinib Mesylate for Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors: 10-Year Experience From Vietnam. Cancer Control. 2019 Jan-Dec;26(1):1073274819863776. doi: 10.1177/1073274819863776. PubMed PMID: 31319677.
[5] Lunge S, Bhise R. Imatinib Mesylate Induced Erythroderma. J Assoc Physicians India. 2018 Dec;66(12):79-80. PubMed PMID: 31313559.
6: Wejih DM, Leila GE, Ali CM, Ramzi N, Ibtissem B, Chadli D. Rectal stromal tumor with an exceptional liver and bone metastatic locations. Pan Afr Med J. 2019 Mar 20;3
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents